ImmunityBio Inc
Company Profile
Business description
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Contact
3530 John Hopkins Court
San DiegoCA92121
USAT: +1 844 696-5235
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
691
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
stocks
Chart of the Week: Aussie dividend yields below 10-year average
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,205.20 | 250.30 | 2.80% |
| CAC 40 | 8,245.75 | 67.86 | 0.83% |
| DAX 40 | 26,540.53 | 102.86 | 0.39% |
| Dow JONES (US) | 53,356.12 | 1,569.40 | 3.03% |
| FTSE 100 | 10,903.60 | 74.39 | 0.69% |
| HKSE | 24,796.98 | 877.48 | 3.67% |
| NASDAQ | 25,736.51 | 364.50 | 1.44% |
| Nikkei 225 | 61,077.90 | 1,110.73 | -1.79% |
| NZX 50 Index | 14,090.97 | 307.52 | 2.23% |
| S&P 500 | 7,688.62 | 119.70 | 1.58% |
| S&P/ASX 200 | 9,065.10 | 230.60 | 2.61% |
| SSE Composite Index | 3,689.91 | 3.74 | 0.10% |